Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer

NCT00391118 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00391118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00391118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
July 31, 2012
Enrollment
153 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, ovarian cancer, peritoneal neoplasm